MBX Biosciences, Inc. SEC filings MBX

MBX Biosciences, Inc. has 232 filings in SEC EDGAR's recent list, going back to May 10, 2019. Its latest annual report, Form ARS, was filed on Apr 22, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 22, 2026 (officer or director change). The company's fiscal year ends on December 31.

MBX Biosciences, Inc. SEC filings
Form Description Filed Period
8-K Current report
Officer or director change
Oct 22, 2026 Oct 20, 2026
8-K Current report
Regulation FD disclosure, Other events
Aug 27, 2026 Aug 27, 2026
10-Q Quarterly report Aug 6, 2026 Jun 30, 2026
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Aug 6, 2026 Aug 6, 2026
8-K Current report
Officer or director change
Jul 13, 2026 Jul 9, 2026
8-K Current report
Regulation FD disclosure, Other events
Jun 12, 2026 Jun 12, 2026
8-K Current report
Officer or director change, Shareholder vote results
Jun 5, 2026 Jun 4, 2026
8-K Current report
Regulation FD disclosure, Other events
May 11, 2026 May 11, 2026
DEFA14A Additional proxy material May 8, 2026 —
8-K Current report
Results of operations
May 7, 2026 May 7, 2026
10-Q Quarterly report May 7, 2026 Mar 31, 2026
ARS Annual report to shareholders Apr 22, 2026 Dec 31, 2025
DEFA14A Additional proxy material Apr 22, 2026 —
DEF 14A Proxy statement Apr 22, 2026 Apr 22, 2026
S-3ASR Automatic shelf registration Mar 12, 2026 —
S-8 Employee stock plan registration Mar 12, 2026 —
10-K Annual report Mar 12, 2026 Dec 31, 2025
8-K Current report
Results of operations
Mar 12, 2026 Mar 12, 2026
8-K Current report
Regulation FD disclosure, Other events
Mar 9, 2026 Mar 9, 2026
8-K Current report
Material agreement, Officer or director change
Feb 27, 2026 Feb 24, 2026
8-K Current report
Other events
Feb 5, 2026 Feb 4, 2026
8-K Current report
Officer or director change, Regulation FD disclosure
Jan 22, 2026 Jan 20, 2026
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jan 12, 2026 Jan 11, 2026
EFFECT Filing Dec 8, 2025 —
CORRESP Letter to the SEC Dec 4, 2025 —
S-3 Shelf registration Nov 6, 2025 —
10-Q Quarterly report Nov 6, 2025 Sep 30, 2025
8-K Current report
Results of operations, Officer or director change
Nov 6, 2025 Oct 31, 2025
8-K Current report
Material agreement
Sep 26, 2025 Sep 24, 2025
424B4 Prospectus Sep 25, 2025 —
EFFECT Filing Sep 24, 2025 —
S-1MEF Filing Sep 24, 2025 —
CORRESP Letter to the SEC Sep 22, 2025 —
CORRESP Letter to the SEC Sep 22, 2025 —
S-1 Registration statement Sep 22, 2025 —
8-K Current report
Regulation FD disclosure, Other events
Sep 22, 2025 Sep 22, 2025
8-K Current report
Regulation FD disclosure, Other events
Sep 4, 2025 Sep 4, 2025
UPLOAD Letter from the SEC Aug 13, 2025 —
DRS Filing Aug 8, 2025 —
10-Q Quarterly report Aug 7, 2025 Jun 30, 2025
8-K Current report
Results of operations
Aug 7, 2025 Aug 7, 2025
8-K Current report
Regulation FD disclosure, Other events
Jun 16, 2025 Jun 16, 2025
8-K Current report
Regulation FD disclosure
Jun 9, 2025 Jun 9, 2025
8-K Current report
Officer or director change, Shareholder vote results
Jun 6, 2025 Jun 5, 2025
10-Q Quarterly report May 12, 2025 Mar 31, 2025
8-K Current report
Results of operations
May 12, 2025 May 12, 2025
ARS Annual report to shareholders Apr 23, 2025 Dec 31, 2024
DEFA14A Additional proxy material Apr 23, 2025 —
DEF 14A Proxy statement Apr 23, 2025 Apr 22, 2025
8-K Current report
Officer or director change, Regulation FD disclosure
Apr 7, 2025 Apr 7, 2025
S-8 Employee stock plan registration Mar 17, 2025 —
10-K Annual report Mar 17, 2025 Dec 31, 2024
8-K Current report
Results of operations
Mar 17, 2025 Mar 17, 2025
8-K Current report
Results of operations, Regulation FD disclosure, Other events
Jan 7, 2025 Jan 7, 2025
10-Q Quarterly report Nov 7, 2024 Sep 30, 2024
8-K Current report
Results of operations
Nov 7, 2024 Nov 7, 2024
8-K Current report
Bylaw or fiscal year change
Sep 16, 2024 Sep 16, 2024
S-8 Employee stock plan registration Sep 13, 2024 —
424B5 Prospectus supplement Sep 13, 2024 —
EFFECT Filing Sep 12, 2024 —
S-1MEF Filing Sep 12, 2024 —
CERT Filing Sep 12, 2024 —
8-A12B Filing Sep 10, 2024 —
CORRESP Letter to the SEC Sep 10, 2024 —
CORRESP Letter to the SEC Sep 10, 2024 —
S-1/A Amended registration statement Sep 9, 2024 —
CORRESP Letter to the SEC Aug 30, 2024 —
S-1/A Amended registration statement Aug 30, 2024 —
UPLOAD Letter from the SEC Aug 30, 2024 —
CORRESP Letter to the SEC Aug 26, 2024 —
CORRESP Letter to the SEC Aug 23, 2024 —
S-1 Registration statement Aug 23, 2024 —
UPLOAD Letter from the SEC Jul 22, 2024 —
DRSLTR Filing Jul 11, 2024 —
DRS/A Filing Jul 11, 2024 —
UPLOAD Letter from the SEC May 7, 2024 —
DRSLTR Filing Apr 26, 2024 —
DRS/A Filing Apr 26, 2024 —
UPLOAD Letter from the SEC Apr 17, 2024 —
DRS Filing Mar 22, 2024 —
D Filing Nov 18, 2022 —
D Filing Jul 27, 2020 —
D/A Filing May 10, 2019 —
D Filing May 10, 2019 —

Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MBX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Carmel, IN
SEC filer status
, Emerging growth company
SEC CIK
1776111

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.